Falk Gastro Info 2/2016

Video

 

Video course abdominal ultrasound

Examination of abdominal vessels

Aorta longitudinal

 

Author: Prof. Dr. Christoph F. Dietrich, Caritas Krankenhaus Bad Mergentheim.

© 2015 Falk Foundation e.V., Freiburg. All rights reserved.

 

 

Please switch on your loudspeakers!

 

 

Link to Falk Mediacenter:

http://media.falkfoundation.de/index.php?id=174&L=1

 

Link to the video directly:

http://media.drfalkpharma.de/fileadmin/media/73_Abdominal_vessels_Aorta_longitudinal_ENG.mp4

 

 

Preview images:

 

580 x 325 pixels (with arrow)

http://newsletter.drfalkpharma.de/FGI_2-16/Vorschau_Sono_Clip73_E_580P.jpg

 

580 x 325 pixels (without arrow)

http://newsletter.drfalkpharma.de/FGI_2-16/Vorschau_Sono_Clip73_E_580.jpg

 

 

 

 

Latest research in brief:

 

Description field (to be displayed at the end of the structural element):

 

 

Bowel

http://newsletter.drfalkpharma.de/Logos/Falk-Darm.png

 

 

Text:

Bharucha AE et al, Am J Gastroenterol. 2015;110(11):1589–96

Temporal trends in diverticulitis: Incidence is increasing, particularly in younger patients, but complications are relatively uncommon.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=22136#30940

 

 

Text:

Münch A et al, Gut. 2016;65(1):47–56

Collagenous colitis: Low-dose budesonide efficiently maintains clinical remission and quality of life over a period of 1 year.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=22136#c30941

 

 

Text:

Coenen MJH et al, Gastroenterology. 2015;149(4):907–17.e7

Thiopurine-associated myelotoxicity in IBD patients: Usefulness of TPMT testing prior to therapy remains controversial.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=22136#c30942

 

 

 


 

Liver
Biliary Tracts

http://newsletter.drfalkpharma.de/Logos/Falk-Leber.png

 

 

Text:

Manka P et al, Clin Gastroenterol Hepatol. 2015;13(10):1836–42

Hepatitis E and acute liver failure: Data from a German University Medical Center indicate that even in Western countries, hepatitis E virus (HEV) infection is an important differential diagnosis in acute liver failure. Serological testing for HEV is not sufficient; HEV RNA should also be determined in order to confirm or rule out HEV infection in patients with acute liver failure of ambiguous etiology.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=22136#c30944

 

 

Text:

Ampuero J et al, Gastroenterology. 2015;149(6):1483–9

Liver cirrhosis: Minimal hepatic encephalopathy is associated with a reduced 5-year survival in patients with cirrhosis. Evaluation of minimal hepatic encephalopathy may help to predict survival and improve management of patients with cirrhosis. The critical flicker frequency may be an adequate diagnostic tool for this purpose.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=22136#c30945

 

 

Text:

Beste LA et al, Gastroenterology. 2015;149(6):1471–82.e5

Cirrhosis and hepatocellular carcinoma (HCC): Data from the US indicate that cirrhosis prevalence and mortality as well as HCC incidence and mortality increased from 2001 to 2013, driven by hepatitis C with smaller contribution from non-alcoholic fatty liver disease (NAFLD). Cirrhosis prevalence may peak in 2021.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=22136#c30946

 

 

 

 


 

Oesophagus

Stomach

Duodenum

http://newsletter.drfalkpharma.de/Logos/Falk-Magen.png

 

 

Text:

Saccone G et al, Am J Obstet Gynecol. 2015 [Epub ahead of print]

Celiac disease and pregnancy: Women with celiac disease are at risk for obstetric complications including preterm birth, stillbirth and growth restriction.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=22136#c30947

 

 

Text:

Molina-Infante J et al, Am J Gastroenterol. 2015;110(11):1567–75

PPI-responsive esophageal eosinophilia: Long-term loss of response is uncommon and influenced by CYP2C19 genotype and rhinoconjunctivitis.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=22136#c30948

 

 

Text:

Asher Wolf W et al, Gastroenterology. 2015;149(7):1752–61.e1

Barrett’s esophagus: very low incidence of esophageal adenocarcinoma and related mortality following radiofrequency ablation.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=22136#c30953

 

 

 

 

Pancreas

http://newsletter.drfalkpharma.de/Logos/Falk-Pankreas.png

 

 

Text:

Krishna SG et al, Am J Gastroenterol. 2015;110(11):1608–19

Acute pancreatitis: Morbid obesity is associated with adverse clinical outcomes including mortality, organ failure and health-care utilization.

 

Link:

http://www.drfalkpharma.com/index.php?L=1&id=22136#c30956

 

 

International Symposia and Workshops

 

 

Symposium 201

Gut-Liver Interactions: From IBD to NASH

 

Bild:

http://newsletter.drfalkpharma.de/Logos/Symposium.jpg

 

Text:

March 11 – 12, 2016, Innsbruck, Austria

Congress Innsbruck, Rennweg 3, 6020 Innsbruck, Austria

 

Link1:

http://newsletter.drfalkpharma.de/Programme/2015/S201_Innsbruck_2016_Preliminary_Program.pdf

 

Link2:

http://newsletter.drfalkpharma.de/Programme/2015/S201_Innsbruck_2016_Registration.pdf

 

Link für Online-Anmeldung:

http://events.falkfoundation.com/index.php?id=205&L=1

 

 

 

 

Symposium 202

Evolving Therapies in Clinical Practice in IBD

 

Bild:

http://newsletter.drfalkpharma.de/Logos/Symposium.jpg

 

Text:

April 29 – 30, 2016, Prague, Czech Republic

Hilton Prague, Pobrezni 1, 18600 Prague 08, Czech Republic

 

Link1:

http://newsletter.drfalkpharma.de/Programme/2015/S202_Prague_2016_Preliminary_Program.pdf

 

Link2:

http://newsletter.drfalkpharma.de/Programme/2015/S202_Prague_2016_Registration.pdf

 

Link für Online-Anmeldung:

http://events.falkfoundation.com/index.php?id=206&L=1

 

 

 

 

Current Falk literature:

 

 

Ursofalk®

Now also licensed for hepatobiliary disorders in cystic fibrosis

(6 pages)

U16e

 

 

Picture:

http://newsletter.drfalkpharma.de/FGI_2-16/U16e_1-4-15.jpg

 

PDF:

http://newsletter.drfalkpharma.de/FGI_2-16/U16e_1-4-15.pdf

 

 

 

 

Order by email (Please replace text by your email address):

 

mailto:text?subject=FGI%22%2F2016:%20Ordering%20of%20brochure%20U16e&body=Please%20send%20the%20brochure%20to%20the%20following%20address:%0A%0A